Literature DB >> 20339893

Myeloperoxidase-antineutrophil cytoplasmic antibody-associated crescentic glomerulonephritis with rheumatoid arthritis: a comparison of patients without rheumatoid arthritis.

Noriaki Kurita1, Naobumi Mise, Akiko Fujii, Masaya Mori, Keiko Sai, Takahiro Nishi, Takeshi Suzuki, Hitoshi Tagawa, Tokuichiro Sugimoto.   

Abstract

BACKGROUND: Several cases of rheumatoid arthritis (RA) with myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA)-associated crescentic glomerulonephritis (CrGN) have been reported. However, its clinical characteristics are not clear.
METHODS: We summarized 3 patients of concurrent RA and MPO-ANCA-associated CrGN, diagnosed in our hospital from 1992 to 2006, and compared their clinicopathological data with those of 10 MPO-ANCA-associated CrGN patients without RA in the same period.
RESULTS: All three RA patients were middle-aged or young adult women with 7-14 years of RA history. The initial clinical symptom was microhematuria, and mean duration from hematuria onset to histological confirmation of CrGN was 17 months. At renal biopsy, serum creatinine concentration (sCr) was modestly elevated, with the mean value of 3.4 mg/dl. Crescents were detected in 30% of glomeruli, whereas advanced glomerular sclerosis, tubular atrophy, and interstitial fibrosis were also observed. In comparison with patients without RA, patients with RA were significantly younger and showed a longer duration from the onset to histological confirmation of CrGN. Serum creatinine concentration at referral was significantly lower; however, estimated glomerular filtration rate (eGFR) was comparable. The Birmingham Vasculitis Activity Score and the Disease Extent Index were significantly lower, and pathological examination showed less crescent formation and a tendency to advanced glomerular sclerosis in patients with RA.
CONCLUSIONS: In patients with RA, MPO-ANCA-associated CrGN appeared to develop at younger ages and often showed a slowly progressive deterioration of the renal function with slight extrarenal manifestations. These smoldering clinical features may result in late referral from rheumatologists to nephrologists and therefore poor prognosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20339893     DOI: 10.1007/s10157-010-0278-z

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  28 in total

1.  [Rheumatoid arthritis associated with microscopic polyangiitis].

Authors:  V Ortiz-Santamaria; A Serra; J Teixido; A Olivé
Journal:  Med Clin (Barc)       Date:  2000-05-27       Impact factor: 1.725

2.  Pauci-immune necrotizing glomerulonephritis complicating rheumatoid arthritis.

Authors:  M U Qarni; D E Kohan
Journal:  Clin Nephrol       Date:  2000-07       Impact factor: 0.975

3.  Antineutrophil cytoplasmic antibodies in patients with early rheumatoid arthritis: an early marker of progressive erosive disease.

Authors:  A Mustila; L Paimela; M Leirisalo-Repo; H Huhtala; A Miettinen
Journal:  Arthritis Rheum       Date:  2000-06

4.  Development and validation of a disease extent index for Wegener's granulomatosis.

Authors:  K de Groot; W L Gross; K Herlyn; E Reinhold-Keller
Journal:  Clin Nephrol       Date:  2001-01       Impact factor: 0.975

Review 5.  Nomenclature of systemic vasculitides. Proposal of an international consensus conference.

Authors:  J C Jennette; R J Falk; K Andrassy; P A Bacon; J Churg; W L Gross; E C Hagen; G S Hoffman; G G Hunder; C G Kallenberg
Journal:  Arthritis Rheum       Date:  1994-02

6.  Systemic rheumatoid vasculitis: a clinical and laboratory study of 50 cases.

Authors:  D G Scott; P A Bacon; C R Tribe
Journal:  Medicine (Baltimore)       Date:  1981-07       Impact factor: 1.889

7.  Chronic rheumatoid arthritis complicated by myeloperoxidase antineutrophil cytoplasmic antibody-associated nephritis.

Authors:  N Yorioka; Y Taniguchi; D Amimoto; H Miyata; M Yamakido; T Taguchi
Journal:  Am J Nephrol       Date:  1999       Impact factor: 3.754

8.  Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis.

Authors:  Anthony Booth; Lorraine Harper; Tariq Hammad; Paul Bacon; Megan Griffith; Jeremy Levy; Caroline Savage; Charles Pusey; David Jayne
Journal:  J Am Soc Nephrol       Date:  2004-03       Impact factor: 10.121

9.  Anti-myeloperoxidase antibodies in patients with rheumatoid arthritis: prevalence, clinical correlates, and IgG subclass.

Authors:  G Cambridge; M Williams; B Leaker; M Corbett; C R Smith
Journal:  Ann Rheum Dis       Date:  1994-01       Impact factor: 19.103

10.  Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis.

Authors:  R A Luqmani; P A Bacon; R J Moots; B A Janssen; A Pall; P Emery; C Savage; D Adu
Journal:  QJM       Date:  1994-11
View more
  5 in total

1.  AP-VAS 2012 case report: two patients with rheumatoid arthritis suspected of relapsed microscopic polyangiitis after initiation of dialysis.

Authors:  Mai Sugahara; Takahiro Nishi; Shinji Tanaka; Noriaki Kurita; Keiko Sai; Tatsuya Kano; Kyosuke Nishio; Tokuichiro Sugimoto; Naobumi Mise
Journal:  CEN Case Rep       Date:  2013-07-04

2.  A case of smoldering antineutrophil cytoplasmic antibody-associated vasculitis development during the course of primary Sjögren's syndrome.

Authors:  Yoichi Iwafuchi; Tetsuo Morioka; Yuko Oyama; Ichiei Narita
Journal:  CEN Case Rep       Date:  2021-11-17

3.  Anti-neutrophil cytoplasmic antibody associated vasculitis in patients with rheumatoid arthritis.

Authors:  Haiting Wu; Yiyun Lu; Rongrong Hu; Wei Ye; Yubing Wen; Jianfang Cai; Hang Li; Xuemei Li
Journal:  BMC Nephrol       Date:  2022-04-22       Impact factor: 2.585

4.  A Case Report Describing a Rare Presentation of Simultaneous Occurrence of MPO-ANCA-Associated Vasculitis and Rheumatoid Arthritis.

Authors:  Nathalie Foray; Tamer Hudali; Muralidhar Papireddy; John Gao
Journal:  Case Rep Nephrol       Date:  2016-11-06

5.  Crescentic glomerular nephritis associated with rheumatoid arthritis: a case report.

Authors:  K Balendran; L D S U Senarathne; R D Lanerolle
Journal:  J Med Case Rep       Date:  2017-07-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.